Title
Drug
Sponsor
Protocol Number
Trial Phase
Status
TitleTrial PhaseProtocol NumberDrugSponsorTrial SiteStatus
A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease Previously Immunized With 23 Valent pneumococcal polysacchride Vaccine.3B1851013 13-valent Pneumoccocal Conjugate VaccinePfizer
  1. King Faisal Specialist Hospital and Research Center (Riyadh)

Completed

Multi-Center Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs Who Have An Inadequate Response to Current Non-Biologic DMARD or Anti-TNF Therapy3bMA21573TocilzumabRoche
  1. King Faisal Specialist Hospital and Research Center (Jeddah)
  2. King Abdulaziz Medical City NG (Jeddah)
  3. King Abdulaziz University Hospital (Jeddah)

Completed

A Randomized, Open-label Phase III Intergroup Study: Effect of Adding Bevacizumab to Cross Over Fluoropyrimidine Based Chemotherapy (CTx) in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line Standard CTx/Bevacizumab Combination3ML18147 BevacizumabRoche
  1. King Fahad Specialist Hospital (Dammam)
  2. King Abdulaziz Hospital and Oncology Center (Jeddah)
  3. King Abdulaziz University Hospital (Jeddah)
  4. King Faisal Specialist Hospital and Research Center (Jeddah)
  5. King Faisal Specialist Hospital and Research Center (Riyadh)

Completed

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multinational Clinical Study to Evaluate the Efficacy and Safety of 2.0 mg/kg/Week and 2.0 mg/kg/Every Other Week BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)3MOR-004BMN 110BioMarin Pharmaceutical Inc.
  1. King Faisal Specialist Hospital and Research Center (Riyadh)

Completed

A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)3MOR-005BMN 110BioMarin Pharmaceutical Inc.
  1. King Faisal Specialist Hospital and Research Center (Riyadh)

Completed

An Open Label, Randomised Phase III Trial of BIBW 2992 and Vinorelbine Versus Trastuzumab and Vinorelbine in Patients With Metastatic HER2-overexpressing Breast Cancer Failing One Prior Trastuzumab Treatment31200.75 BIBW 2992 / Vinorelbine / TrastuzumabBoehringer Ingelheim
  1. King Fahad Medical City (Riyadh)
  2. International Medical Center (Jeddah)
  3. King Abdulaziz Medical City NG (Riyadh)
  4. King Abdulaziz Medical City NG (Jeddah

Completed

V212-001 A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients With Solid Tumor or Hematologic Malignancy3V212-011V212MSD
  1. King Fahad Specialist Hospital (Dammam)

Completed

Phase IIb Primary Vaccination Study to Evaluate Non-Inferiority & Persistence of the Immune Response of GSK Biologicals' MenACWY Conjugate Vaccine (Intramuscularly) vs Mencevax ACWY (Subcutaneously) to Healthy Subjects (11-55 Years of Age)3b107402Meningococcal ACWY Conjugate VaccineGsk
  1. King Abdulaziz Medical City NG (Riyadh)

Completed

Tocilizumab Efficacy and Safety in RA Patients After Inadequate Response to DMARDs or Anti-TNF3 ML22726TocilizumabRoche
  1. King Fahad Specialist Hospital (Dammam)
  2. King Fahad Medical City (Riyadh)
  3. King Abdulaziz University Hospital (Jeddah)
  4. Hira Hospital (Makkah)

Completed

Efficacy and Safety of Irbesartan/Amlodipine Fixed Combination Therapy Compared With Irbesartan Monotherapy in Hypertensive Patients Uncontrolled on Irbesartan 150 mg Monotherapy3IRBAM_R_04219Irbesartan AmlodipineSanofi
  1. King Abdulaziz Medical City NG (Jeddah)

Completed

12345...الأخيرة